Clinical Trial Update: Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

View source ↗

Summary

A completed clinical trial update notes sub-optimal responses to anti-TNF therapies in inflammatory bowel disease, including ulcerative colitis and Crohn's dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Certolizumab pegol (certolizumab pegol)
• Golimumab (golimumab)
• Infliximab (infliximab)

Snippet

Sponsor: Takeda | Conditions: Colitis, Ulcerative, Crohn Disease | Status: COMPLETED